| Karen Mcgoldrick, MD | |
|
450 Veterans Memorial Pkwy, East Providence, RI 02914-5300 | |
| (401) 434-7853 | |
| Not Available |
| Full Name | Karen Mcgoldrick |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 44 Years |
| Location | 450 Veterans Memorial Pkwy, East Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154341212 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD5870 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Women & Infants Hospital Of Rhode Island | Providence, RI | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern New England Healthcare For Women, Llc | 0042486649 | 32 |
News Archive
The House of Representatives approved a measure by voice vote Wednesday that "instructs U.S. directors at the International Monetary Fund and other global development institutions to use their votes and influence to cancel Haiti's debt," CongressDaily reports (4/15).
Supported by a National Institutes of Health grant worth a projected $3.3 million over five years, Wake Forest Baptist Medical Center investigators have expanded their research into the cumulative effects of head impacts in young football players to the high school level.
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.
› Verified 8 days ago
| Entity Name | Affinity Physicians Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184944662 PECOS PAC ID: 0244413391 Enrollment ID: O20110326000053 |
News Archive
The House of Representatives approved a measure by voice vote Wednesday that "instructs U.S. directors at the International Monetary Fund and other global development institutions to use their votes and influence to cancel Haiti's debt," CongressDaily reports (4/15).
Supported by a National Institutes of Health grant worth a projected $3.3 million over five years, Wake Forest Baptist Medical Center investigators have expanded their research into the cumulative effects of head impacts in young football players to the high school level.
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.
› Verified 8 days ago
| Entity Name | Southern New England Healthcare For Women, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699058826 PECOS PAC ID: 0042486649 Enrollment ID: O20120103000614 |
News Archive
The House of Representatives approved a measure by voice vote Wednesday that "instructs U.S. directors at the International Monetary Fund and other global development institutions to use their votes and influence to cancel Haiti's debt," CongressDaily reports (4/15).
Supported by a National Institutes of Health grant worth a projected $3.3 million over five years, Wake Forest Baptist Medical Center investigators have expanded their research into the cumulative effects of head impacts in young football players to the high school level.
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.
› Verified 8 days ago
| Entity Name | Tollgate Obstetrics And Gynecology Midwifery Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528403847 PECOS PAC ID: 6204076896 Enrollment ID: O20130702000374 |
News Archive
The House of Representatives approved a measure by voice vote Wednesday that "instructs U.S. directors at the International Monetary Fund and other global development institutions to use their votes and influence to cancel Haiti's debt," CongressDaily reports (4/15).
Supported by a National Institutes of Health grant worth a projected $3.3 million over five years, Wake Forest Baptist Medical Center investigators have expanded their research into the cumulative effects of head impacts in young football players to the high school level.
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen Mcgoldrick, MD 450 Veterans Memorial Pkwy, East Providence, RI 02914-5300 Ph: (401) 751-5111 | Karen Mcgoldrick, MD 450 Veterans Memorial Pkwy, East Providence, RI 02914-5300 Ph: (401) 434-7853 |
News Archive
The House of Representatives approved a measure by voice vote Wednesday that "instructs U.S. directors at the International Monetary Fund and other global development institutions to use their votes and influence to cancel Haiti's debt," CongressDaily reports (4/15).
Supported by a National Institutes of Health grant worth a projected $3.3 million over five years, Wake Forest Baptist Medical Center investigators have expanded their research into the cumulative effects of head impacts in young football players to the high school level.
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.
› Verified 8 days ago
Dr. Marc Alexander Jaffe, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 38 Amaral St, East Providence, RI 02915 Phone: 401-438-3300 Fax: 401-434-5313 | |
Harris Galkin, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 450 Veterans Memorial Pkwy, East Providence, RI 02914 Phone: 401-434-7853 | |
Santina Siena, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 450 Veterans Memorial Pkwy, East Providence, RI 02914 Phone: 401-434-7747 Fax: 401-434-7891 | |
Marguerite Vigliani, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 450 Veterans Memorial Pkwy, Suite 101, East Providence, RI 02914 Phone: 401-438-1748 |